These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 24577164)

  • 21. Differential inhibition of tumor angiogenesis by tie2 and vascular endothelial growth factor receptor-2 dominant-negative receptor mutants.
    Stratmann A; Acker T; Burger AM; Amann K; Risau W; Plate KH
    Int J Cancer; 2001 Feb; 91(3):273-82. PubMed ID: 11169947
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Concurrent bevacizumab with a sequential regimen of doxorubicin and cyclophosphamide followed by docetaxel and capecitabine as neoadjuvant therapy for HER2- locally advanced breast cancer: a phase II trial of the NSABP Foundation Research Group.
    Rastogi P; Buyse ME; Swain SM; Jacobs SA; Robidoux A; Liepman MK; Pajon ER; Dy PA; Posada JG; Melnik MK; Piette F; Geyer CE; Mamounas EP; Wolmark N
    Clin Breast Cancer; 2011 Aug; 11(4):228-34. PubMed ID: 21684812
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anthracyclines in Early Breast Cancer: The ABC Trials-USOR 06-090, NSABP B-46-I/USOR 07132, and NSABP B-49 (NRG Oncology).
    Blum JL; Flynn PJ; Yothers G; Asmar L; Geyer CE; Jacobs SA; Robert NJ; Hopkins JO; O'Shaughnessy JA; Dang CT; Gómez HL; Fehrenbacher L; Vukelja SJ; Lyss AP; Paul D; Brufsky AM; Jeong JH; Colangelo LH; Swain SM; Mamounas EP; Jones SE; Wolmark N
    J Clin Oncol; 2017 Aug; 35(23):2647-2655. PubMed ID: 28398846
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Semi-quantitative evaluation of estrogen receptor expression is a strong predictive factor of pathological complete response after anthracycline-based neo-adjuvant chemotherapy in hormonal-sensitive breast cancer.
    Petit T; Wilt M; Velten M; Rodier JF; Fricker JP; Dufour P; Ghnassia JP
    Breast Cancer Res Treat; 2010 Nov; 124(2):387-91. PubMed ID: 20824324
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High baseline Tie1 level predicts poor survival in metastatic breast cancer.
    Tiainen L; Korhonen EA; Leppänen VM; Luukkaala T; Hämäläinen M; Tanner M; Lahdenperä O; Vihinen P; Jukkola A; Karihtala P; Aho S; Moilanen E; Alitalo K; Kellokumpu-Lehtinen PL
    BMC Cancer; 2019 Jul; 19(1):732. PubMed ID: 31340773
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer.
    Miles DW; de Haas SL; Dirix LY; Romieu G; Chan A; Pivot X; Tomczak P; Provencher L; Cortés J; Delmar PR; Scherer SJ
    Br J Cancer; 2013 Mar; 108(5):1052-60. PubMed ID: 23422754
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bevacizumab plus neoadjuvant chemotherapy in patients with HER2-negative inflammatory breast cancer (BEVERLY-1): a multicentre, single-arm, phase 2 study.
    Bertucci F; Fekih M; Autret A; Petit T; Dalenc F; Levy C; Romieu G; Bonneterre J; Ferrero JM; Kerbrat P; Soulie P; Mouret-Reynier MA; Bachelot T; Lerebours F; Eymard JC; Deblock M; Lortholary A; Hardy-Bessard AC; Barthelemy P; Bonnefoi H; Charafe-Jauffret E; Bidard FC; Viens P; Lemonnier J; Pierga JY
    Lancet Oncol; 2016 May; 17(5):600-11. PubMed ID: 27032301
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancer.
    von Minckwitz G; Eidtmann H; Rezai M; Fasching PA; Tesch H; Eggemann H; Schrader I; Kittel K; Hanusch C; Kreienberg R; Solbach C; Gerber B; Jackisch C; Kunz G; Blohmer JU; Huober J; Hauschild M; Fehm T; Müller BM; Denkert C; Loibl S; Nekljudova V; Untch M; ;
    N Engl J Med; 2012 Jan; 366(4):299-309. PubMed ID: 22276820
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pathologic response to short intensified taxane-free neoadjuvant chemotherapy in patients with highly proliferative operable breast cancer.
    Le Tourneau C; Dettwiler S; Beuzeboc P; Alran S; Laurence V; Pierga JY; Fréneaux P; Sigal-Zafrani B; Diéras V; Vincent-Salomon A
    Am J Clin Oncol; 2012 Jun; 35(3):242-6. PubMed ID: 21358298
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Assessment of early response biomarkers in relation to long-term survival in patients with HER2-negative breast cancer receiving neoadjuvant chemotherapy plus bevacizumab: Results from the Phase II PROMIX trial.
    Kimbung S; Markholm I; Bjöhle J; Lekberg T; von Wachenfeldt A; Azavedo E; Saracco A; Hellström M; Veerla S; Paquet E; Bendahl PO; Fernö M; Bergh J; Loman N; Hatschek T; Hedenfalk I;
    Int J Cancer; 2018 Feb; 142(3):618-628. PubMed ID: 28940389
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and Safety of Neoadjuvant Treatment with Bevacizumab, Liposomal Doxorubicin, Cyclophosphamide and Paclitaxel Combination in Locally/Regionally Advanced, HER2-Negative, Grade III at Premenopausal Status Breast Cancer: A Phase II Study.
    Tampaki EC; Tampakis A; Alifieris CE; Krikelis D; Pazaiti A; Kontos M; Trafalis DT
    Clin Drug Investig; 2018 Jul; 38(7):639-648. PubMed ID: 29744672
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MYC Amplification as a Predictive Factor of Complete Pathologic Response to Docetaxel-based Neoadjuvant Chemotherapy for Breast Cancer.
    Pereira CBL; Leal MF; Abdelhay ESFW; Demachki S; Assumpção PP; de Souza MC; Moreira-Nunes CA; Tanaka AMDS; Smith MC; Burbano RR
    Clin Breast Cancer; 2017 Jun; 17(3):188-194. PubMed ID: 28089283
    [TBL] [Abstract][Full Text] [Related]  

  • 33. High expression of class III β-tubulin predicts good response to neoadjuvant taxane and doxorubicin/cyclophosphamide-based chemotherapy in estrogen receptor-negative breast cancer.
    Wang Y; Sparano JA; Fineberg S; Stead L; Sunkara J; Horwitz SB; McDaid HM
    Clin Breast Cancer; 2013 Apr; 13(2):103-8. PubMed ID: 23218766
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of biology-based breast cancer types with distinct predictive and prognostic features: role of steroid hormone and HER2 receptor expression in patients treated with neoadjuvant anthracycline/taxane-based chemotherapy.
    Darb-Esfahani S; Loibl S; Müller BM; Roller M; Denkert C; Komor M; Schlüns K; Blohmer JU; Budczies J; Gerber B; Noske A; du Bois A; Weichert W; Jackisch C; Dietel M; Richter K; Kaufmann M; von Minckwitz G
    Breast Cancer Res; 2009; 11(5):R69. PubMed ID: 19758440
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Gene expression profile and angiogenic marker correlates with response to neoadjuvant bevacizumab followed by bevacizumab plus chemotherapy in breast cancer.
    Yang SX; Steinberg SM; Nguyen D; Wu TD; Modrusan Z; Swain SM
    Clin Cancer Res; 2008 Sep; 14(18):5893-9. PubMed ID: 18794102
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Abnormal angiopoietins 1&2, angiopoietin receptor Tie-2 and vascular endothelial growth factor levels in hypertension: relationship to target organ damage [a sub-study of the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)].
    Nadar SK; Blann A; Beevers DG; Lip GY
    J Intern Med; 2005 Oct; 258(4):336-43. PubMed ID: 16164572
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Circulating tumour cells and pathological complete response: independent prognostic factors in inflammatory breast cancer in a pooled analysis of two multicentre phase II trials (BEVERLY-1 and -2) of neoadjuvant chemotherapy combined with bevacizumab.
    Pierga JY; Bidard FC; Autret A; Petit T; Andre F; Dalenc F; Levy C; Ferrero JM; Romieu G; Bonneterre J; Lerebours F; Bachelot T; Kerbrat P; Campone M; Eymard JC; Mouret-Reynier MA; Gligorov J; Hardy-Bessard AC; Lortholary A; Soulie P; Boher JM; Proudhon C; Charafe-Jaufret E; Lemonnier J; Bertucci F; Viens P
    Ann Oncol; 2017 Jan; 28(1):103-109. PubMed ID: 28177480
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Analysis of soluble angiogenic factors in Crohn's disease: a preliminary study.
    Dueñas Pousa I; Maté Jiménez J; Salcedo Mora X; Abreu MT; Moreno Otero R; Gisbert JP
    Gastroenterol Hepatol; 2007 Nov; 30(9):518-24. PubMed ID: 17980128
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype.
    Symmans WF; Wei C; Gould R; Yu X; Zhang Y; Liu M; Walls A; Bousamra A; Ramineni M; Sinn B; Hunt K; Buchholz TA; Valero V; Buzdar AU; Yang W; Brewster AM; Moulder S; Pusztai L; Hatzis C; Hortobagyi GN
    J Clin Oncol; 2017 Apr; 35(10):1049-1060. PubMed ID: 28135148
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Patient and tumor characteristics associated with breast cancer recurrence after complete pathological response to neoadjuvant chemotherapy.
    Ju NR; Jeffe DB; Keune J; Aft R
    Breast Cancer Res Treat; 2013 Jan; 137(1):195-201. PubMed ID: 23149464
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.